FDA ADVISORY-COMMITTEE SYSTEM EVALUATED

被引：0
作者：
不详
机构：
来源：
LANCET | 1993年 / 341卷 / 8836期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：45 / 45
页数：1
相关论文
共 50 条
[1]   IOM ENDORSES FDA ADVISORY-COMMITTEE SYSTEM [J].
FOX, JL .
BIO-TECHNOLOGY, 1993, 11 (02) :154-155
[2]   FDA ARTHRITIS ADVISORY-COMMITTEE MEETING [J].
PAULUS, HE .
ARTHRITIS AND RHEUMATISM, 1982, 25 (09) :1124-1125
[3]   FDA ARTHRITIS ADVISORY-COMMITTEE MEETING [J].
PAULUS, HE .
ARTHRITIS AND RHEUMATISM, 1982, 25 (05) :595-596
[4]   SELECTION OF FDA ADVISORY-COMMITTEE MEMBERS [J].
PODELL, LB .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1983, 40 (10) :1614-1614
[5]   FDA ARTHRITIS ADVISORY-COMMITTEE MEETING [J].
PAULUS, HE .
ARTHRITIS AND RHEUMATISM, 1983, 26 (10) :1288-1289
[6]   FDA ARTHRITIS ADVISORY-COMMITTEE MEETING [J].
PAULUS, HE .
ARTHRITIS AND RHEUMATISM, 1985, 28 (04) :450-451
[7]   FDA ADVISORY-COMMITTEE RECOMMENDS EARLIER USE OF ZIDOVUDINE [J].
不详 .
CLINICAL PHARMACY, 1990, 9 (04) :248-248
[8]   FDA ARTHRITIS ADVISORY-COMMITTEE MEETING - THERAFECTIN - ROLE OF ARTHRITIS ADVISORY-COMMITTEE IN FDA REVIEW PROCESS - PERSONNEL CHANGES - ISSUES OF OVER-THE-COUNTER SWITCHING [J].
FURST, DE ;
PAULUS, HE .
ARTHRITIS AND RHEUMATISM, 1994, 37 (09) :1408-1409
[9]   FUNDAMENTALLY SOUND FDA ADVISORY-COMMITTEE SYSTEM EXPECTS TO USE MOST IMPROVEMENT IDEAS [J].
MARWICK, C ;
GUNBY, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (02) :198-198
[10]   ADVISORY-COMMITTEE ON PESTICIDES [J].
CHALLIS, T .
FOOD AND CHEMICAL TOXICOLOGY, 1991, 29 (09) :649-650
12345